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Abstract
To assess the long-term effects of juvenile idiopathic arthritis in adulthood, unified diagnostic methods for articular and
extra-articular lesions should be used which depend on the juvenile idiopathic arthritis variants, the disease activity and
treatment.
The objective of the research was to compare the clinical manifestations in adult patients with different juvenile idiopathic
arthritis-specific immunogenic markers and to evaluate their impact on the long-term articular and extra-articular damage.
Materials and methods. We observed 132 young patients with different juvenile idiopathic arthritis variants. According
to genetic/immunological markers the following groups were formed: Group I - 38 positive human leukocyte antigen B27
patients; Group II - 13 positive antinuclear antibody patients; Group III - 26 positive rheumatoid factor/anti-cyclic citrullinated
peptide patients and Group IV - 55 patients with all negative markers. Long-term effects of juvenile idiopathic arthritis were
estimated by the articular juvenile arthritis damage index (JADI-A) and the extra-articular juvenile arthritis damage index
(JADI-E). Descriptive statistics, the Student’s T-test, the Fisher’s exact test and Mann-Whitney U-test were performed.
Results. 70 women and 62 men with the disease duration of 13.6±9.3 years at the age of 24.3±8.3 years were included into
the study: 12 (9.1%) patients with positive rheumatoid factor polyarthritis, 30 (22.7%) patients - with negative rheumatoid
factor polyarthritis, 32 (24.2%) patients with persistent oligoarthritis, 19 (14.4%) patients with extendent oligoarthritis, 20
(15.2%) patients with entesitis-related arthritis and 19 (14.4%) patients with systemic arthritis; there were no patients with
psoriatic arthritis. There were no differences between groups in age, disease-modifying antirheumatic drug cumulative dose,
mean dose of prednisolone and quality of life according to the SF-36. In Group I, the delay in the diagnosis was more than
one year (18.6±24.2 months). In this group, less painful (p<0.005) and deformed (p<0.01) joints as compared to Group III,
and higher levels of the ESR and C-reactive protein as compared to Group IV were found, although the Juvenile Arthritis
Disease Activity Score index in childhood was lower (p<0.005) as compared to Group II. They received a lower cumulative
dose of the glucocorticoids as compared to Group II (p<0.01), respectively. They had lower (p<0.01) JADI-E as compared
to Group II (1.31 ± 1.49) and lower (p <0.01) JADI-A as compared to Group III. In Group III, the diagnosis was made the
fastest in comparison with other groups (6.4±8.4 months, p<0.05); more painful joints (p <0.05) and ankylosis (p<0.05)
were observed as compared to Group I, JADI-A was significantly higher (p<0.05) in Group III as compared to Group I. The
most pronounced JADI-A was found in Group III, while in Group I and Group II, this index was the lowest. JADI-E was the
most pronounced in Group II, and the most favorable course was found in Group I and Group III (p<0.05).
Conclusions. Presence of anti-cyclic citrullinated peptide/rheumatoid factor in adults with juvenile idiopathic arthritis has
negative impact on joint damage (JADI-A) indicating the need for aggressive therapy in both childhood and adulthood.
Presences of antinuclear antibodies are associated with more often extra-articular damages in adulthood as compared to
other groups.
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Problem statement and analysis of the
recent research
The clinical course of juvenile idiopathic arthritis (JIA) de-
pends on one of the seven JIA variants. However, JIA is
usually unpredictable and can lead to the disease remission
as well as to severe complications and hence handicaps and
social incapacitation in both childhood and adulthood. To
evaluate long-term effects of JIA in adulthood, we should
use unified methods to diagnose articular and extra-articular
damage. They depend not only on JIA variant, disease ac-
tivity, and the level of damage to the target organ due to the
pathologic process, but also on the received therapy, its ef-
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fectiveness, dosage, and duration [3]. Most frequently, side
effects are the result of a long-term treatment with glucocor-
ticoids (GC), as well as the absence of adequate response
to basic disease modifying synthetic and immune-biological
drugs [3]. On the other hand, unfavourable prognostic factors
in JIA that lead to handicaps are hip joint damage, cervical
spine involvement, and the development of uveitis [10]. In
2005, Viola S. et al. [12] published their research where they
developed and validated the Juvenile Arthritis Damage Index
(JADI) for articular (JADI-A) and extra-articular (JADI-E)
damage in JIA. They included the assessment of functional
disorders or the development of ankyloses, the presence of
prostheses in the temporomandibular joints, the cervical spine,
the shoulder joints, the elbow joints, the radiocarpal joints,
the metacarpophalangeal joints, the proximal interphalangeal
joints, the hip joints, the knee joints, the talocrural joints, and
the metatarsal phalangeal joints. The evaluation of long-term
extra-articular effects of JIA focused on eye lesions (the pres-
ence of cataract and/or other uveitis complications with vision
loss), the musculoskeletal system (the development of consid-
erable muscle atrophy, osteoporosis with vertebral fractures
or compressions, aseptic necrosis of bones, severe spinal cur-
vature deformation due to the contraction of the hip joint or
change in extremity length, significant change in extremity
length or bone growth problems), the skin (stria, atrophy of
hypodermic tissue due to the intra-articular injection of corti-
costeroids), the endocrine system (growth disorders, pubertal
development disorders, diabetes mellitus) and the develop-
ment of amyloidosis. In addition to the clinical picture, there
are certain immunological markers used for the diagnostics
of different JIA variants, i.e., positive or negative rheumatoid
factor (RF), immunoglobulin G (IgG) antibodies to cyclic
cytrullinated peptide (A-CCP), antinuclear antibody (ANA),
human leukocyte antigen B27 (HLA-B27). The research of
their impact on the long-term effects of JIA in adulthood is of
great importance.
The objective of the research was to compare clinical
symptoms and received therapy in adult patients with different
JIA specific immunogenic markers (RF, A-CCP, ANA, NLA-
B27), as well as to evaluate their influence on the development
of long-term articular and extra-articular damage.
1. Materials and methods
We observed 132 young patients with different JIA variants
in the Oleksandrivska Municipal Clinical Hospital, Kyiv. The
patients’ height, weight, body mass index (BMI), the delay
in the diagnosis from the onset of clinical manifestations, dis-
ease duration, disease activity in childhood and adulthood
according to the Juvenile Arthritis Disease Activity Score
(JADAS) [1] and the Disease Activity Score-28 (DAS 28), the
patients’ general condition in childhood and adulthood accord-
ing to the visual analogue scale (VAS), treatment with GC and
disease-modifying antirheumatic drugs (DMARDs), as well as
immune-biological therapy (IBT) received in childhood were
analyzed. We studied medical documentation to determine
the localization of joint syndrome in childhood and adulthood,
the presence of enthesitis, sacroilitis, spinal pain, uveitis in
both childhood and adulthood. Quality of life was evaluated
using the 36-Item Short Form Health Survey (SF-36) and
the degree of functional impairment was assessed using the
Health Assessment Questionnaire (HAQ). Long-term effects
of JIA were estimated by the articular juvenile arthritis dam-
age index (JADI-A) and the extra-articular juvenile arthritis
damage index (JADI-E) [12].
All patients underwent fasting blood tests for the follow-
ing indices: quantitative C-reactive protein (CRP) (latex test,
Roche Diagnostics), HLA-B27 (flow cytometry method on the
FACScan using monoclonal anti-HLA B27 antibodies (Bec-
ton Dickinson), RF (Immunoglobulin M (IgM) autoantibodies
to Fc fragment of IgG) using the Euroimmun enzyme-linked
immunosorbent assay (ELISA), IgG antibodies to A-CCP by
flow cytofluorometry using BioPlex 2200 testing (the Bio-Rad
testing system), and ANA by immunofluorescence method
using the Euroimmun EUROStar III Plus.
Statistical analysis was performed using descriptive statis-
tics, the Student’s t test for random sampling, the Fisher’s
exact test for small sample size. The comparison of para-
metric indicators was performed using the Mann-Whitney U
test, since the distribution of the samples’ parametric indices
was not Gaussian (according to the Shapiro-Wilk test). We
used the program ”Statistica 6.0” Copyright c© StatSoft, Inc.
1984-2001.
2. Results
There were 70 women and 62 men at the age of 24.3±8.3
years with the disease duration of 13.6±9.3 years. The aver-
age height was 1.70±1.08 m, body weight - 62.3±14.9 kg,
the BMI - 21.1±13.5. According to International League
of Associations for Rheumatology (ILAR) classification of
JIA, there were 12 (9.1%) patients with RF (+) polyarthritis,
30 (22.7%) patients with RF (-) polyarthritis, 32 (24.2%) pa-
tients with persistent oligoarthritis, 19 (14.4%) patients with
extended oligoarthritis, 20 (15.2%) patients with enthesitis-
related arthritis, and 19 (14.4%) patients with systemic arthri-
tis; there were no patients with psoriatic arthritis. The analysis
of immunological marker frequency in different JIA variants
showed the following results: HLA-B27 was detected in 38
(28.8% of all patients with JIA) patients, RF and/or A-CCP -
in 26 (19.6%) patients, ANA - in 13 (9.8%) patients; all the
markers were negative in 55 (41.7%) patients.
To detect the difference between patients with different
immunologic/genetic markers irrespective of the ILAR variant
of JIA, we formed groups of adult patients with JIA accord-
ing to specific genetic/immunologic markers, i.e., Group I -
38 HLA-B27 positive patients; Group II - 13 ANA positive
patients; Group III - 26 RF and/or A-CCP positive patients;
and Group IV - 55 patients with all negative markers (Table
1).
Table 1 demonstrates that there was no difference be-
tween groups in age, DMARD cumulative dose, mean dose
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Figure 1. Long-term effects of articular and extra-articular
damage in adult patients with juvenile idiopathic arthritis
with different immunogenic markers
of prednisolone and quality of life according to the SF-36
questionnaire. However, in HLA-B27 positive patients, the
disease started at an older age (12.3±3.3 years of age) than in
other groups (p<0.0005) and its duration was lower (9.5±6.9
years) in comparison with other groups (p<0.005), although
the delay in the diagnosis from the onset of clinical manifes-
tations was noted more often (p<0.005) than in the group of
RF/A-CCP positive patients.
In HLA-B27 positive patients, the delay in the diagnosis
was more than one year (18.6±24.2 months). In this group,
less painful (p<0.005) and deformed (p<0.005) joints were
found as compared to RF and/or A-CCP positive patients,
and higher levels of the ESR (21.6±17.5 mm/h) and CRP
(28.4±42.9 mg/h) were registered as compared to Group IV
(11.3±11.9 mm/h and 7.3±10.9 mg/h, respectively), although
the JADAS index in childhood was lower (p<0.005) as com-
pared to ANA positive patients. Thus, due to the lower labora-
tory and clinical data they received a lower (p<0.005) cumula-
tive dose of GC (2203.9±4546.9 mg) as compared with ANA
positive patients (6516.6±5396.2 mg). That is probably the
reason of lower (p<0.005) long-term extra-articular damage
index in adulthood (JADI-E) (0.50±1.06 mg) as compared
to ANA positive patients (1.31±1.49) and lower (p <0.005)
long-term articular damage index (JADI-A) in adulthood as
compared to A-CCP/RF positive patients (3.0±4.9).
In the group of A-CCP/RF+ patients, the diagnosis was
made the fastest in comparison with other groups (6.4±8.4
months, p<0.05), they had more painful joints (p<0.05) and
ankyloses (p<0.05) as compared to HLA-B27+ group. This
contributed to a significantly higher JADI-A (p<0.05) in A-
CCP/RF+ patients as compared to HLA-B27+ group.
The most pronounced joint damage (JADI-A) in adults
with JIA was found in the group of A-CCP/RF positive pa-
tients, whereas in HLA-B27 and ANA positive patients, this
index was the lowest with less long-term effects. Extra-
articular damage (JADI-E) was the most pronounced in the
group of ANA-positive patients, and the most favourable
course was found in A-CCP/RF and HLA-B27 positive pa-
tients (Fig. 1).
3. Discussion
132 adult patients with JIA were included in the study (with
the mean disease duration of 13.6 ± 9.3 years). 21.2% of pa-
tients had disease duration ≥20 years. There are scarce long-
term observations of patients with JIA [6, 8, 9, 13] mostly
carried out in pre-biologic era. 21.9% of patients included
in tour study underwent IBT in childhood or adulthood and
most patients continued to take DMARDs or undergo IBT,
59.9% of adult patients had active disease. This exceeded the
data presented by Selvaag AM, et al [9], who informed that
41% of patients with JIA had active disease after 30 years
of observation, as well as the data of another investigation,
which registered 37-43% of patients with active disease [13].
Oliver’s-Ramas et al. [5] registered 67% of patients with ac-
tive disease in adulthood. The researchers attribute the higher
percentage to the fact that to assess disease activeness, they
applied scales introduced for rheumatic diseases in adulthood.
However, unlike our research, they did not observe patients
with more favourable JIA prognosis - persistent oligoarthritis
most of whom develop remission. Our study is consistent
with the research carried out by other scientists who investi-
gated prognostic unfavourable factors for the clinical course
of rheumatoid arthritis. These are positive RF and/or A-CCP
alongside with a high disease activeness and early structural
damage [2, 11]. Although these data refer to the prognosis of
rheumatoid arthritis, our research confirmed the hypothesis of
negative influence of RF and/or A-CCP based on the study of
JIA patients [3].
4. Conclusions
Despite the early diagnosis in childhood, in adults with RF/A-
CCP (+) JIA, greater number of joints were damaged and
deformed as compared to other groups.
The most pronounced joint damage (JADI-A) as a result
of JIA in adulthood was found in A-CCP/RF (+) patients
indicating the need for aggressive therapy in both childhood
and adulthood.
ANA (+) patients with JIA more often develop extra-
articular damage in adulthood, which is probably due to the
higher disease activity according to the JADAS in childhood
and higher cumulative dose of glucocorticoids as compared
to other groups.
5. Prospects for further research
Further researches of prognostic unfavourable factors in adult
patients with JIA are needed.
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Table 1. Distribution of adult patients with JIA according to specific genetic/immunologic markers
HLA-B27 ANA A-CCP /RF All markers negative
Indices M±SD, n=38 M±SD, n=13 M±SD, n=26 M±SD, n=55
(Group I) (Group II) (Group III) (Group IV)
Age at the moment of examina-
tion
23.6±6.7 20.8±3.9 23.7±7.3 22.9±7.2
Height, m 1.7±0.1 1.7±0.1 1.7±0.1 1.7±0.1
Weight, kg 68.9±13.0* 57.2±9.7 59.2±9.9** 60.7±16.2***
BMI, kg/m2 22.31±4.33 20.41±2.35 20.48±2.38 21.13±3.80
Age in the debut of the disease,
years
12.3±3.3* 9.9±4.9 9.5±3.8** 7.5±5.1***
Period of delay in the diagnosis,
months
18.6±24.2 28.9±46.9# 6.4±8.4** 14.1±23.9
Duration of the disease, years 9.5±6.9 10.9±7.4 13.9±7.7** 14.6±9.1***
Painful joints (number) 3.3±3.6 2.7±4.5 6.2±5.9** 2.1±3.7
Deformed joints/ ankyloses
(number)
0.4±1.0 0.8±1.5 1.7±2.9** 0.9±1.8
ESR in the debut of the disease
mm/h
45.3±91.0 21.3±15.4 26.3±17.8 29.2±22.3
ESR at the moment of examina-
tion, mm/h
21.6±17.5 17.0±17.2 22.8±20.3 11.3±11.9***
CRP in the debut of the disease,
mg/l
25.6±26.5 19.6±19.7 24.4±33.3 31.1±29.2
CRP at the moment of examina-
tion, mg/l
28.4±42.9 22.1±51.2 24.9±41.2 7.3±10.9***
Patient’s/doctor’s evaluation of
general condition in childhood
(VAS), mm
62.5±21.7/ 52.1±18.2 77.1±16.0/ 61.4±10.7 60.0±23.3/ 52.5±19.1 68.4±21.6/ 54.4±19.0
Patient’s/doctor’s evaluation of
general condition in adulthood
(VAS), mm
40.5±25.3/ 33.4±24.6 38.9±21.8/ 31.5±24.1 36.9±17.9/ 32.5±25.6 33.1±25.1/ 24.8±21.6
DAS28 in adulthood 3.2±1.5 2.9±1.3 3.7±1.5& 2.7±1.3
JADAS in childhood 12.9±6.6* 19.3±6.0 15.0±7.5 15.3±9.1
JADAS in adulthood 9.1±6.2 10.8±6.9$ 10.7±9.1& 7.1±5.3
Permanent dose of pred-
nisolone, mg
5.8±2.4 9.0±12.5 9.2±5.8 3.7±5.7
Cumulative dose of GC, mg 2203.9±4546.9* 6516.6±5396.2 4475.7±7598.4 12443.3±48063.6
Cumulative dose of DMARDs,
years
4.9±4.9 5.1±3.4 5.4±6.4 5.5±5.8
JADI-A 1.1±1.9 0.9±2.3 3.0±4.9** 1.9±5.1
JADI-E 0.50±1.06* 1.31±1.49# 0.38±0.7 0.73±1.55
Quality of life according to SF-
36 PCS/MCS
44.0±11.3/ 45.6±13.5 47.3±9.6/ 46.1±10.6 44.3±7.9/ 46.0±9.5 45.6±10.3/ 46.5±9.6
Notes:
ESR – erythrocyte sedimentation rate; CRP – C-reactive protein; VAS – visual analogue scale; BMI – body mass index; GC –
glucocorticoids; JADI-A – articular juvenile arthritis damage index; JADI-E – extra-articular juvenile arthritis damage index; JADAS –
Juvenile Arthritis Disease Activity Score;
* – reliable differences (p<0.05) between HLA-B27- and ANF-positive patients;
** – reliable differences (p<0.05) between HLA-B27- and A-CCP/RF-positive patients;
*** – reliable differences (p<0.05) between HLA-B27-positive and all other markers negative patients;
# – reliable differences (p<0.05) between ANA- and A-CCP-positive patients;
& – reliable differences (p<0.05) between A-CCP/RF-positive and all markers negative patients.
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